AB Science SA announced the issuance of a Canadian patent protecting the composition of matter of AB8939, including its use for treating acute myeloid leukemia $(AML.AU)$, with protection extending until 2036. This patent ensures comprehensive intellectual property coverage for AB8939 across critical markets, including the USA, Europe, China, Japan, South Korea, and more. Additionally, AB8939 has received orphan drug designation for AML from both the European Medicines Agency and the US FDA, providing market exclusivity post-approval. A secondary medical use patent application was filed to protect AB8939's use in treating AML with specific chromosomal abnormalities, potentially extending protection until 2044 for these patient sub-populations.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.